Genmab A/S (GMAB) PT Lowered to $48 at Truist Securities
Tweet Send to a Friend
Truist Securities analyst Asthika Goonewardene lowered the price target on Genmab A/S (NASDAQ: GMAB) to $48.00 (from $49.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
